UroGen Pharma URGN Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Net margin | -94.8%+45.0pp | -139.8%+30.8pp | -170.6%-6.1pp | -164.4%-13.8pp | -150.7%-10.3pp | |
| Free cash flow margin | -118.2%+30.0pp | -148.2%-5.1pp | -143.1%-12.0pp | -131.1%-14.2pp | -116.9%-9.5pp | |
| Returns | ||||||
| Return on assets | -53.2%+10.0pp | -63.1%+4.5pp | -67.6%-4.4pp | -63.2%-1.4pp | -61.8%-7.1pp | |
| Efficiency | ||||||
| Asset turnover | 0.6×+0.1× | 0.5×+0.1× | 0.4×0.0× | 0.4×0.0× | 0.4×0.0× | |
| Liquidity | ||||||
| Current ratio | 4.7×+0.7× | 4×0.0× | 4×-0.2× | 4.1×-1.5× | 5.6×-0.4× | |
| Quick ratio | 4.3×+0.6× | 3.7×-0.1× | 3.8×-0.2× | 4×-1.5× | 5.5×-0.3× | |
| Cash ratio | 2.2×-0.2× | 2.4×+0.3× | 2.1×+0.2× | 2×-0.5× | 2.5×-1.3× | |
| Leverage | ||||||
| Debt-to-assets | 0.8×+0.1× | 0.6×-0.1× | 0.7×+0.1× | 0.6×+0.1× | 0.5×+0.1× | |
| Valuation | ||||||
| Market capitalization | $875.31M-20.2% | $1.1B+18.8% | $922.97M+45.2% | $635.82M+24.7% | $509.8M+13.4% | |
| Enterprise value | $962.43M-13.7% | $1.12B+15.9% | $962.87M+43.6% | $670.39M+26.0% | $532.13M+32.1% | |
| Price / sales | 6.2×-3.8× | 10×+0.4× | 9.6×+2.8× | 6.7×+1.2× | 5.5×+0.6× | |
| EV / sales | 6.9×-3.3× | 10.2×+0.2× | 10×+2.9× | 7.1×+1.3× | 5.8×+1.3× | |
| Free cash flow yield | -19%-4.1pp | -14.8%+0.1pp | -15%+4.5pp | -19.4%+1.6pp | -21.1%+0.5pp | |
| Earnings yield | -15.2%-1.2pp | -14%+3.8pp | -17.8%+6.5pp | -24.4%+2.8pp | -27.2%+1.1pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are UroGen Pharma's profit margins?
- UroGen Pharma (URGN) runs a 89.7% gross margin and a -329.7% operating margin, with a -94.8% net margin.
- Where do UroGen Pharma's ratios come from?
- Every ratio is computed from UroGen Pharma's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
